Biocon Announces U.S. Commercial Debut of Bosaya™ and Aukelso™, Its Denosumab Biosimilars Biocon Limited, a global innovation-driven biopharmaceutical organization, has announced the commercial launch of two denosumab biosimilars—Bosaya™ and Aukelso™—in…
Shionogi Highlights Real-World Effectiveness of Fetroja/Fetcroja Against MBL-Producing Enterobacterales at ESCMID Global 2026 Shionogi & Co., Ltd. has unveiled new real-world and surveillance data highlighting the clinical utility of cefiderocol…
Gilead to Acquire Tubulis to Enhance Oncology Portfolio with Potentially Best-in-Class ADC and Advanced Platform Gilead Sciences has announced that it has entered into a definitive agreement to acquire Tubulis…
B Capital Selected by AMED as Registered VC to Advance Japan’s Drug Development Ecosystem B Capital, a multi-stage investment firm with a strong focus on healthcare innovation, has announced that…
Acadia Pharmaceuticals Expands U.S. Access to DAYBUE STIX for Patients with Rett Syndrome Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) for oral solution—a newly developed powder formulation of its…
CaryHealth Introduces Direct-to-Patient Access Program for Natroba in Collaboration with Cipher Pharmaceuticals CaryHealth, a leading provider of integrated digital healthcare solutions, has announced the launch of a new direct-to-patient (DTP)…
TriSalus Life Sciences Names Richard Marshall, MD, Chief Medical Officer TriSalus Life Sciences, a clinical-stage oncology company focused on integrating innovative drug delivery technologies with standard-of-care therapies and immunotherapeutic approaches,…
Amy Koch Joins Propel Health Medical Affairs as Senior Vice President, Client Services Propel Health Medical Affairs (PHMA), a full-service scientific communications agency operating within the broader Propel Health ecosystem,…
Endospan Secures U.S. Food and Drug Administration Approval for NEXUS® Aortic Arch Stent Graft System Endospan, a privately held innovator focused on advancing endovascular therapies for complex aortic conditions, has…
GenSight Biologics Provides Update on Cash Position and Early Access Program Revenue as of March 31, 2026 GenSight Biologics, a clinical-stage biopharmaceutical company dedicated to the development and commercialization of…
Stoke Therapeutics Announces Appointment of Dr. Clare Kahn to Its Board of Directors Stoke Therapeutics, a clinical-stage biotechnology company focused on restoring protein expression through RNA-based medicines, has announced the…
Amgen Shares Positive Topline Phase 3 Data for Subcutaneous TEPEZZA® in Adults with Moderate-to-Severe Active Thyroid Eye Disease Amgen (NASDAQ: AMGN) has announced positive topline results from a pivotal Phase…